In an attempt to prevent generic versions of drugs from reaching the market, pharmaceutical companies are refusing to sell their drugs to generic drug makers, according to the New York Times. Federal regulators say the tactic is illegal, and the Federal Trade Commission has become involved in a legal case over the issue involving drug maker Actelion (ALIOF), the newspaper noted.
- Pharmaceuticals & Drug Trials
- pharmaceutical companies
- Federal Trade Commission